.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,948,437

« Back to Dashboard
Patent 5,948,437 protects SEROQUEL XR and is included in one NDA. There have been four Paragraph IV challenges on Seroquel XR. There are four tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for SEROQUEL XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 5,948,437

Title: Pharmaceutical compositions using thiazepine
Abstract:The invention relates to sustained release formulations comprising 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo[b,f] [1,4]thiazepine or a pharmaceutically acceptable salt thereof, to methods of treating psychotic states and hyperactivity utilizing the sustained release formulations and to a process for preparing the sustained release formulations.
Inventor(s): Parikh; Bhavnish Vinod (Hockessin, DE), Timko; Robert Joseph (West Chester, PA), Addicks; William Joseph (Morgantown, WV)
Assignee: Zeneca Limited (GB)
Application Number:08/864,306
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Use; Process; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 46th percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca
SEROQUEL XR
quetiapine fumarate
TABLET, EXTENDED RELEASE;ORAL022047-001May 17, 2007RXNo5,948,437*PED► subscribeY
Astrazeneca
SEROQUEL XR
quetiapine fumarate
TABLET, EXTENDED RELEASE;ORAL022047-005Aug 11, 2008RXNo5,948,437*PED► subscribeY
Astrazeneca
SEROQUEL XR
quetiapine fumarate
TABLET, EXTENDED RELEASE;ORAL022047-002May 17, 2007RXYes5,948,437*PED► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc